BidaskClub cut shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research note published on Tuesday morning.

Shares of Atrion (NASDAQ ATRI) traded up $9.40 on Tuesday, hitting $630.00. The stock had a trading volume of 14,636 shares, compared to its average volume of 3,007. The stock has a market cap of $1,180.00, a PE ratio of 36.88 and a beta of 0.85. Atrion has a fifty-two week low of $454.10 and a fifty-two week high of $694.00.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings data on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share (EPS) for the quarter. The business had revenue of $37.90 million during the quarter. Atrion had a return on equity of 18.34% and a net margin of 22.98%.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Stockholders of record on Friday, December 1st were paid a $1.20 dividend. This represents a $4.80 annualized dividend and a dividend yield of 0.76%. The ex-dividend date was Thursday, November 30th. Atrion’s payout ratio is presently 26.59%.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc boosted its stake in shares of Atrion by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock valued at $216,000 after buying an additional 14 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Atrion by 0.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 6,183 shares of the medical instruments supplier’s stock valued at $3,978,000 after buying an additional 19 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Atrion by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 66 shares during the period. Voya Investment Management LLC boosted its stake in shares of Atrion by 10.2% in the 2nd quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock valued at $486,000 after buying an additional 70 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Atrion by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 10,258 shares of the medical instruments supplier’s stock valued at $6,600,000 after buying an additional 76 shares during the period. Institutional investors and hedge funds own 59.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/16/atrion-atri-lowered-to-sell-at-bidaskclub.html.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.